Tax Reversal Lifts Charles River Labs’ Profit Sixfold as Wilmington Drug Tester Raises 2026 Outlook
Charles River Laboratories earned $6.86 a share in Q3 2026, boosted by a $245.6 million tax reversal; organic revenue grew 4.7% and it raised its 2026 outlook.